1. P519: TRANSFUSION INDEPENDENCE AMONG NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX-BASED COMBINATIONS VS OTHER THERAPIES: RESULTS FROM THE AML REAL WORLD EVIDENCE (ARC) INITIATIVE. (23rd June 2022) Authors: Wolach, O.; Garcia, J. S.; Vachhani, P.; Zeidner, J.; Lai, C.; Moshe, Y.; Xavier, M.; Lee, S.; Zuckerman, T.; Pollyea, D. A.; Abedin, S.; Chen, E. C.; Bathini, S.; Edwards, W.; Bui, C. N.; Cheng, W. W.-H.; Svensson, A.; Guérin, A.; Maitland, J.; Ma, E. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 418 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML. (23rd June 2022) Authors: Daver, N.; Maris, M.; Ramchandren, R.; Bixby, D.; Doucette, K.; Mawad, R.; Egan, D.; Stevens, D.; Zonder, J.; Molloy, N.; Scheuber, A.; Bruns, I.; Mantzaris, I.; Konopleva, M.; Goldberg, A. D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1700 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗